Jefferies Underperform on AMAG Pharmaceuticals

Jefferies & Co. is out with a research report on AMAG Pharmaceuticals

and it has an Underperform rating and a $12 price target on shares. In a note to clients, Jefferies & Co. writes, "Management changes and expense alignment (vs. slow Feraheme sales) are positive. However, shareholders could be better served if AMAG divests Feraheme, returns its value & current cash (~$11.8/sh) to shareholders, in our view. Excluding $3M in Medicaid reserve estimate, 3Q11 Feraheme sales of $12.8M (~flat q/q). Our revenue estimate changes are due to failed merger with ALTH (removing Folotyn estimates)." Shares of AMAG are up $2.48 to $16.23, a gain of 18.04%‎.